A Young Mother’s Fight: Why One Family Wants a New Cancer Drug on the NHS

When Fionnuala Quinlan‑Bennett was diagnosed with aggressive breast cancer at just 28, the future seemed terrifyingly short. By June, the disease had spread to her bones and liver, and the 32‑year‑old lost her battle.

Her husband, Nathan Bennett, now carries a painful question: what if a treatment existed that could have bought her a few more months, maybe even years? The drug in question is Enhertu – a combination of a targeted monoclonal antibody and a chemotherapy agent called deruxtecan. It’s already approved in Scotland and several other nations, but not on England’s NHS.

“It’s heartbreaking knowing that a medicine is out there and I can’t get it for my wife,” Nathan recalled, his voice wavering. “She would hear about it, and the knowledge that it was out of reach was a kind of quiet torture.”

Fionnuala, who loved travel, books and dreaming about the children she hoped to raise, asked her loved ones to honor her memory by living fully. “If you want to remember me, go out with a smile and make a difference,” she told family and friends.

Breast Cancer Now, a UK charity, says making Enhertu available could help roughly 1,000 women in England each year. Holly Heath, its head of policy and evidence, stressed the urgency: “These women don’t have time to wait. We need a swift, decisive deal now.”

The National Institute for Health and Care Excellence (NICE) previously ruled the drug not cost‑effective at its price, but a 2025 US‑UK trade agreement raised the threshold for value judgments. NICE now says discussions with the drug’s manufacturer and NHS England have resumed, aiming for a commercial agreement that could finally bring Enhertu to patients in England.

For the Bennetts, the fight is personal, but it also reflects a broader debate about how quickly life‑extending therapies should be adopted. As they push for change, they hope no other family will have to watch a loved one slip away while a potential lifeline sits just out of reach.